FST and breast carcinoma: It is also notable that activins have well-established morphogen roles during normal development [44], and that previous work has reported increased INHBA/activin-A activity at the leading edge of HER2-positive breast tumors [45] and that follistatin (Fig. 7f) can suppress HER2-positive breast cancer metastasis [46].